Get In Touch
info@pbgbiopharma.com
Work Inquiries
info@pbgbiopharma.com

The Benefits and Risks of a Cannabis Prescription for Chronic Non-Cancer Pain 

 

A group of researchers from Israel investigated whether cannabis usage was associated with reduced opioid usage. They also evaluated the risk of opioid and cannabis use disorders among chronic non-cancer pain patients who had been prescribed medical cannabis.

A random sample of chronic pain patients were interviewed by telephone about their opioid and cannabis usage. Cannabis and opioid use disorders were assessed with Portenoy’s criteria, a self‐report questionnaire for assessing addiction among pain patients treated with opioids.

The study found that, of the 100 participants, 76 had used opiods at some point. Of this group, 93% decreased or stopped opioids following cannabis initiation. Ten patients (10%) met the criteria for cannabis use disorder. Participants meeting this criteria had higher lifetime depression and less education compared to those who did not meet the criteria.

The study concluded that cannabis usage was associated with reduced opioid usage in chronic non-cancer pain patients. The cannabis use disorder was more prevalent among the younger participants who also had a lower study compliance rate, suggesting the higher actual prevalence of cannabis use disorder. The researchers suggested that while medical cannabis may help reduce opioid use in chronic non-cancer pain patients, younger age, depression, and other risk factors should be carefully evaluated before cannabis is prescribed.

Reference

  1. Zloczower, O., Brill, S., Zeitak, Y. & Peles, E. Risk and benefit of cannabis prescription for chronic non-cancer pain. J Addict Dis 1–11 (2021) doi:10.1080/10550887.2021.1956673.

https://pubmed.ncbi.nlm.nih.gov/34338621/ 

 

close

The freshest cannabis content, right to your inbox.

Sign up to receive the latest developments in cannabis science every week.

We don’t spam! Read our privacy policy for more info.

Author avatar
Dr. Dan Jin
Dr. Dan Jin is the resident Cannabis Research Scientist at PBG BioPharma. She has over 10 publications to her name in the field of cannabis research. She is a passionate force in researching novel uses of cannabis and educating the public about the potential of this incredible plant.

Post a comment

Your email address will not be published. Required fields are marked *

We use cookies to give you the best experience.